Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 3/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16816237 | 1.00 | PRKAB2 (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| Hydrochloric Acid SCHEMBL30629865 | 0.99 | PRKAB2 (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16815890 | 0.93 | PRKAG1 (0.36) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL30629859 | 0.93 | PRKAG1 (0.36) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16815891 | 0.93 | PRKAG1 (0.36) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16815892 | 0.92 | PRKAG1 (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16815894 | 0.92 | PRKAG1 (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL30629829 | 0.92 | PRKAG1 (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16815813 | 0.87 | PRKAB2 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL16815814 | 0.87 | PRKAB2 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083611-B1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI SA (FR) | 2019-02-13 | — | — | EP | claimed |
| US-10077237-B2 | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases | SANOFI (FR) | 2018-09-18 | — | — | US | claimed |
| US-20160311770-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI (FR) | 2016-10-27 | — | — | US | claimed |
| EP-3083611-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | Sanofi (FR) | 2016-10-26 | — | — | EP | claimed |
| WO-2015091937-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI (FR) | 2015-06-25 | — | — | WO | claimed |
| EP-2886541-A1 | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases | SANOFI (FR) | 2015-06-24 | — | — | EP | claimed |
| WO-2023196640-A1 | OXINDOLE DERIVATIVES AS AMPK ACTIVATORS FOR USE IN THE TREATMENT OF RARE BLOOD DISORDERS | BIOVERATIV THERAPEUTICS INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3083611-B1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI SA (FR) | 2019-02-13 | — | — | EP | disclosed |
| US-10077237-B2 | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases | SANOFI (FR) | 2018-09-18 | — | — | US | disclosed |
| US-20160311770-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI (FR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311770-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI (FR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311770-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI (FR) | 2016-10-27 | — | — | US | disclosed |
| EP-3083611-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | Sanofi (FR) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091937-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI (FR) | 2015-06-25 | — | — | WO | disclosed |
| EP-2886541-A1 | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases | SANOFI (FR) | 2015-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077237-B2 | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases | PRKAB1, PRKAB2, PRKAG3 | PRKAB2 2/4885PRKAG1 4/4885PRKAA2 9/4885 |
| US-20160311770-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | PRKAB1, PRKAB2, PRKAG3 | PRKAB2 2/4885PRKAG1 4/4885PRKAA2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.